Skip to content
Calculator
Evidence: HighPeptideFDA ApprovedCyclic 11-amino-acid peptideFDA-approved 1983 · SandimmuneCalcineurin inhibitor

Cyclosporine

The fungal cyclic peptide that made organ transplantation routine

Cyclosporine is a ring of 11 amino acids made by a soil fungus. It blocks calcineurin inside T cells, and in 1983 it became the drug that turned organ transplantation into routine care. It is also used for severe autoimmune disease and, as eye drops, for dry eye.

Manufacturer's recommended dosing (FDA label): 2.5 mg/kg/day, up to 4 mg/kg/day, Twice daily, divided, Oral Details ↓

Overview

What is it?

Cyclosporine was found in the 1970s in a fungus from a soil sample, and its ability to suppress the immune system without killing bone marrow cells set it apart from earlier drugs. It is a cyclic peptide of eleven amino acids. It binds a protein called cyclophilin, and the pair blocks calcineurin, an enzyme T cells need to switch on interleukin-2. FDA approved it as Sandimmune in 1983.

Its arrival changed transplant medicine. In a 1983 trial of 209 kidney recipients, one-year graft survival was 80.4% on cyclosporine against 64.0% on the azathioprine-based standard. Tacrolimus, the other calcineurin inhibitor, has been tested against it: in lung transplant trials tacrolimus lowered chronic rejection, at the cost of more new diabetes. Treating brain-dead donors with cyclosporine did not protect their kidneys after transplant.

Neoral, a better-absorbed formulation approved in 1995, is not interchangeable with Sandimmune milligram for milligram, which the labels stress; Neoral is always taken twice daily on a consistent schedule with meals, and grapefruit raises levels. For rheumatoid arthritis and psoriasis the label starts at 2.5 mg/kg a day, rising slowly to at most 4 mg/kg, and stops it if there is no benefit by 16 weeks in arthritis.

Outside transplantation it is a workhorse of immunology, with mixed comparative evidence. In acute severe colitis, pooled trials found it no better or worse than its comparators; in membranous nephropathy, rituximab matched it at a year and kept far more patients in remission at two (60% against 20% in the MENTOR trial); in aplastic anaemia, adding luspatercept sped responses. In chronic hives, mostly uncontrolled studies found about three in four patients responding by 12 weeks, with side effects rising with dose, and its use in atopic keratoconjunctivitis rests on three small trials. Not every new use has held up: a single intravenous dose before angioplasty for a heart attack (CIRCUS, 970 patients) did not improve one-year outcomes, and given with clot-busting treatment for stroke it did not shrink infarcts overall.

The price of that power is toxicity. The labels warn of kidney damage, high blood pressure, infections and cancers, and many drug interactions through CYP3A4; blood levels are monitored, and in arthritis and psoriasis people with impaired kidney function should not receive it. As eye drops, the dose reaching the blood is tiny: Restasis is one drop in each eye twice a day, about 12 hours apart, and it performed like diquafosol in pooled dry-eye studies. A Cochrane review of 17 placebo-controlled trials puts the rise in mean blood pressure at about 5 mmHg at 1-4 mg/kg a day and 11 mmHg above 10 mg/kg; in healthy volunteers grapefruit juice raised exposure by about 53% and pomelo juice by 23%, while orange juice did not change it.

80.4% vs 64.0%
One-year kidney graft survival
1983 trial, 209 patients · PMID 6350878
2.5 → 4 mg/kg
Neoral range in RA and psoriasis
Label
~8.4 h
Terminal half-life in blood
Neoral label
Science

Mechanism of Action

Cyclosporine is a cyclic peptide that blocks calcineurin through cyclophilin, switching off T-cell activation.

🔗

Cyclophilin binding

Forms a complex with cyclophilin inside T cells.

🛑

Calcineurin block

The complex inhibits calcineurin, so NFAT cannot switch on interleukin-2 and T cells stay quiet.

🧪

CYP3A4

Metabolised by CYP3A4, so many drugs and grapefruit change its levels (Neoral label).

Evidence

Published Research

The studies behind cyclosporine, from their PubMed abstracts.

Human1983

The transplant trial that changed the field

In 209 cadaveric kidney recipients, predicted one-year graft survival was 80.4% with cyclosporine and prednisone against 64.0% with azathioprine-based standard therapy (P = 0.003), and patient survival 96.6% against 86.4%.

PMID: 6350878
Human1998

Neoral against Sandimmune

In a randomised double-blind study in kidney recipients, more patients on Sandimmune needed dose increases to keep blood levels in range in the first 3 months; blood pressure, creatinine and cyclosporine-related adverse events did not differ.

PMID: 9645802
Human1995

Added to methotrexate in rheumatoid arthritis

In severe rheumatoid arthritis not controlled by methotrexate, adding cyclosporine improved tender and swollen joint counts by 25% against placebo, with gains in pain, disability and global disease activity.

PMID: 7791814
Human2000

Eye drops for dry eye

In two multicentre randomised trials, cyclosporine 0.05% and 0.1% eye emulsions gave significantly greater improvement than vehicle in corneal staining and Schirmer tear values, two objective signs of moderate to severe dry eye.

PMID: 10768324
Human2026

Treating brain-dead kidney donors

In the Cis-A-Rein trial, giving cyclosporine to brain-dead donors did not reduce delayed graft function in 643 kidney recipients (17.0% against 13.9% on placebo) or change one-year graft survival.

PMID: 41504889
Human2026

Aplastic anaemia with luspatercept

In 58 patients with non-severe aplastic anaemia, adding luspatercept to cyclosporine raised response at 3 months (69.0% against 37.9%) and 6 months, though the difference at the end of follow-up was not significant.

PMID: 42057135
Human2015

Before heart-attack angioplasty: no benefit

In the CIRCUS trial, 970 patients with anterior ST-elevation myocardial infarction and a blocked culprit artery were randomised to an intravenous cyclosporine bolus (2.5 mg/kg) or placebo before PCI; at one year the composite of death, heart-failure events or adverse left-ventricular remodelling occurred in 59.0% against 58.1% (odds ratio 1.04), with no difference in recurrent infarction, unstable angina, stroke or safety.

PMID: 26321103
Human2019

Membranous nephropathy: rituximab held remission longer

In MENTOR, 130 patients with membranous nephropathy and proteinuria of at least 5 g a day were randomised to rituximab or oral cyclosporine (from 3.5 mg/kg a day for 12 months); remission at 12 months was similar (60% against 52%, noninferior), but at 24 months 60% on rituximab and 20% on cyclosporine were in complete or partial remission, and serious adverse events occurred in 17% against 31% (P = 0.06).

PMID: 31269364
Human2015

Stroke: infarcts no smaller overall

In a single-blinded trial of 127 patients with anterior-circulation stroke treated with thrombolysis, an intravenous cyclosporine bolus (2.0 mg/kg) did not significantly reduce infarct volume on MRI at 30 days (median 21.8 against 28.8 mL), though infarcts were smaller in the subgroup with proximal occlusion and effective recanalization.

PMID: 25948727
Review2002

How it was discovered

An account of cyclosporine's discovery in a fungal soil sample at Sandoz and its early pharmacology, including the finding that it suppressed lymphocytes without the bone-marrow toxicity of earlier immunosuppressants.

PMID: 12422576
Review2025

Lung transplant: against tacrolimus

Across four trials of 662 lung transplant recipients, tacrolimus lowered chronic allograft dysfunction (relative risk 0.46) and likely acute rejection compared with cyclosporine, with no clear mortality difference but more new diabetes.

PMID: 40216413
Review2025

Acute severe colitis

A meta-analysis of six randomised trials found no significant difference in clinical response, colectomy or serious adverse events between cyclosporine and its comparators in colitis; most trials had a high risk of bias.

PMID: 41065960
Review2025

Membranous nephropathy

Across eight studies of 936 patients with idiopathic membranous nephropathy, rituximab was overall as effective as cyclophosphamide or cyclosporine, and more effective than cyclosporine in Asian populations.

PMID: 41351015
Review2026

Dry eye: against diquafosol

In six studies of 724 patients with dry eye, topical cyclosporine and diquafosol gave similar improvements in corneal staining and tear break-up time.

PMID: 41804812
Review2018

Chronic hives: 18 studies pooled

Pooling 18 studies (909 patients, only two of them randomised) of cyclosporine in chronic spontaneous urticaria, response at low to moderate doses rose from 54% at 4 weeks to 73% at 12 weeks, and adverse events were dose dependent: 6%, 23% and 57% of patients on very low (under 2 mg/kg a day), low and moderate (4-5 mg/kg) doses; the authors urge caution given the few, limited studies.

PMID: 28916431
Review2010

Blood pressure: 17 placebo-controlled trials

A Cochrane review of 17 double-blind placebo-controlled trials found cyclosporine raises blood pressure in a dose-related way, by about 5 mmHg in mean pressure at 1-4 mg/kg a day and 11 mmHg above 10 mg/kg a day, with a similar rise after a single dose in three trials; the authors advise the lowest effective dose for anyone taking it long term.

PMID: 20091657
Review2012

Atopic keratoconjunctivitis: three small trials

A Cochrane review found only three randomised trials (58 participants) of topical cyclosporine for atopic keratoconjunctivitis: one showed benefit on signs and symptoms, one on signs only and one none, and one of the two that measured it cut steroid use; no serious adverse events were reported, though stinging and eyelid maceration were.

PMID: 22972132
Review2016

Grapefruit and pomelo juice raise exposure

Pooling seven randomised studies in healthy volunteers, grapefruit juice raised cyclosporine exposure (AUC) by about 53% and peak concentration by 24%, pomelo juice raised AUC by 23%, and orange juice had no significant effect on any measure.

PMID: 27278683
Dosing

Dosing Data

Neoral is taken by mouth twice daily on a consistent schedule; transplant doses are set by blood levels, and arthritis and psoriasis doses start at 2.5 mg/kg/day. Restasis is an eye drop.

Prescription immunosuppressant with kidney, blood-pressure, infection and cancer warnings; Neoral and Sandimmune are not interchangeable.
ProtocolDoseFrequencyDurationRoute
Label: rheumatoid arthritis (Neoral) Approved labelNeoral (cyclosporine, modified) US prescribing information (DailyMed set 94461af3, effective August 10, 2026)2.5 mg/kg/day, up to 4 mg/kg/dayTwice daily, dividedStop if no benefit by 16 weeksOral
Label: psoriasis (Neoral) Approved labelNeoral (cyclosporine, modified) US prescribing information (DailyMed set 94461af3, effective August 10, 2026)2.5 mg/kg/day (1.25 mg/kg twice daily), up to 4 mg/kg/dayTwice dailyAt least 4 weeks before increasingOral
Label: dry eye (Restasis) Approved labelRestasis Multidose (cyclosporine ophthalmic emulsion 0.05%) US prescribing information (DailyMed set 7224d810, effective August 21, 2025)1 drop 0.05% in each eyeTwice daily, about 12 hours apartOngoingOphthalmic

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

Dosed by weight and blood level
Oral cyclosporine is prescribed in mg/kg and adjusted to trough blood levels in transplant patients; there is nothing to reconstitute.
Open Calculator →
For Buyers

What a Buyer Needs to Know

What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.

What is sold

The approved product, as its label describes it:

  • Neoral and Filled Neoral (cyclosporine capsule and solution): Neoral ® Soft Gelatin Capsules (cyclosporine capsules, USP) MODIFIED 25 mg Oval, blue-gray imprinted in red, “Neoral” over “25 mg.” Packages of 30 unit-dose blisters. 100 mg Oblong, blue-gray imprinted in red, “NEORAL” over “100 mg.” Packages of 30 unit-dose blisters. Forms the label lists: capsules, bottles and syringes.

Source: Neoral and Filled Neoral (cyclosporine capsule and solution) label, section 16 (DailyMed version 30, effective August 10, 2026).

Mixing a vial: a worked example

Nothing to mix: the label gives Neoral and Filled Neoral (cyclosporine capsule and solution) as capsules, bottles and syringes. Its section 2 includes dilution steps for some uses; those are done where it is given, not at home.

Source: Neoral and Filled Neoral (cyclosporine capsule and solution) label, sections 2, 3 and 16 (DailyMed version 30, effective August 10, 2026).

Storage before and after mixing

Before mixing or first use: “Store and Dispense In the original unit-dose container at controlled room temperature 68°F to 77°F (20°C to 25°C).” “Do not store in the refrigerator.”

After mixing or first use: “Neoral Oral Solution (cyclosporine oral solution, USP) MODIFIED–Recommendations for Administration To make Neoral Oral Solution (cyclosporine oral solution, USP) MODIFIED more palatable, it should be diluted with orange or apple juice that is at room temperature.”

The label also sets storage out in a table that does not read well out of context: see section 16 of the label linked below.

Source: Neoral and Filled Neoral (cyclosporine capsule and solution) label, sections 16 and 2 (DailyMed version 30, effective August 10, 2026).

How it is taken

As the approved label gives it: Oral (Twice daily, divided; Label: rheumatoid arthritis (Neoral)); Ophthalmic (Twice daily, about 12 hours apart; Label: dry eye (Restasis)).

Source: Manufacturer's recommended dosing (FDA label): the route and frequency of each row in Dosing Data below.

What to expect, and when

How long it stays in the body: a half-life of terminal half-life about 8.4 hours (range 5 to 18) in blood. After about five half-lives almost none is left.

How long the doses were given: Label: rheumatoid arthritis (Neoral): Stop if no benefit by 16 weeks; Label: psoriasis (Neoral): At least 4 weeks before increasing.

When effects appear: unknown; no source on this page gives a time to effect for Cyclosporine. Results reported in the studies are under Published Research.

Source: half-life: Neoral prescribing information, Clinical Pharmacology (DailyMed set 94461af3, effective August 10, 2026); Manufacturer's recommended dosing (FDA label), the duration of each row in Dosing Data below.

Side effects, and when to stop or get help

From the Side Effects section: Kidney function changes and high blood pressure, monitored through treatment; Adverse events comparable between the two oral formulations in the 1998 trial. Full list and cautions ↓

Boxed warning on the label: Warning.

When to stop or get help: unknown; the label's warnings summary we read gives no rule for stopping Cyclosporine. Treat a severe or unexpected reaction as a reason to stop and see a doctor.

Source: Neoral and Filled Neoral (cyclosporine capsule and solution) label, boxed warning and section 5 (DailyMed version 30, effective August 10, 2026); the Side Effects section below (“From the studies above”).

Interactions

  • drugs that raise cyclosporine levels (for example diltiazem, verapamil, fluconazole, itraconazole, ketoconazole, azithromycin, clarithromycin, methylprednisolone, allopurinol, amiodarone): higher cyclosporine concentrations; monitor levels and adjust the dose
  • grapefruit and grapefruit juice: raise cyclosporine concentrations and should be avoided
  • drugs and supplements that lower cyclosporine levels (for example rifampin, carbamazepine, phenytoin, phenobarbital, St. John's wort, octreotide, orlistat, terbinafine): lower cyclosporine concentrations and possible loss of effect; monitor levels
  • drugs that may worsen kidney function (for example gentamicin, tobramycin, vancomycin, amphotericin B, ciprofloxacin, tacrolimus, NSAIDs such as diclofenac and naproxen): additive risk of kidney dysfunction; monitor closely
  • potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor blockers and potassium-containing drugs: risk of high potassium; caution, and avoid potassium-sparing diuretics

4 more in the interaction matrix.

Every peptide's record, with its source: the interaction matrix.

Source: Novartis. NEORAL (cyclosporine capsules, modified) US prescribing information, Clinical Pharmacology and Precautions, Drug Interactions. DailyMed version effective August 10, 2026, read October 5, 2026.

Checking what you bought

Unknown: no published independent test of Cyclosporine products is in our lab-results database yet, so how products sold under this name measure up is not known.

To read a certificate of analysis, paste it into the COA decoder; it checks the measured mass against Cyclosporine's expected mass, 1,202.6 Da, from this entry's molecular data. Trust & Verification explains what independent testing can and cannot show.

Legal status

US: FDA Approved (Approved in the US as Sandimmune (Novartis), NDA 050573, on November 14, 1983, for prevention of organ rejection). Sport: Not on the 2026 List.

Country by country ↓ · Regulatory tracker

Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.

Safety

Side Effects & Contraindications

Reported Side Effects

From the studies above.

● Kidney function changes and high blood pressure, monitored through treatment
● Adverse events comparable between the two oral formulations in the 1998 trial

Contraindications & Cautions

Warnings from the Sandimmune and Neoral labels (DailyMed, read October 3, 2026).

● Boxed warning: to be prescribed by physicians experienced in immunosuppression; Sandimmune and Neoral are not interchangeable without monitoring
● Kidney damage and high blood pressure
● Serious infections and cancers, including lymphoma and skin cancer
● Many drug interactions; grapefruit raises blood levels
Questions

Frequently Asked Questions

?Is cyclosporine a peptide?

Yes. It is a ring of 11 amino acids made by a fungus, including several unusual ones, which is why it survives digestion well enough to work as a capsule.

?What is the difference between Sandimmune and Neoral?

Neoral is a modified formulation that is absorbed more consistently. The labels say the two are not interchangeable milligram for milligram, so switching needs blood-level monitoring.

?Is Restasis the same drug?

Restasis is cyclosporine as an eye emulsion for chronic dry eye. Very little reaches the bloodstream, so it does not carry the systemic risks of the capsules.

?Why does grapefruit matter?

Grapefruit and its juice slow cyclosporine's breakdown and raise blood levels, so the Neoral label says to avoid them; many medicines that act on CYP3A4 do the same or the opposite.

?How long before it works in arthritis or psoriasis?

In rheumatoid arthritis the label says onset is generally 4 to 8 weeks, and it should be stopped if there is no benefit by 16 weeks; psoriasis doses are held at least 4 weeks before increasing.

Bibliography

References

  1. [fda] US FDA, Drugs@FDA (openFDA): SANDIMMUNE, NDA 050573 (November 14, 1983); NEORAL, NDA 050715 (July 14, 1995); RESTASIS, NDA 050790 (December 23, 2002). Read October 3, 2026.
  2. [fda-pi] FDA. Sandimmune (cyclosporine) US prescribing information (DailyMed set 5e5926a7-1de0-4b54-a5c0-286b6200ff82, version 37, effective July 10, 2026). Read October 3, 2026.
  3. [fda-pi] FDA. Neoral (cyclosporine, modified) US prescribing information (DailyMed set 94461af3-11f1-4670-95d4-2965b9538ae3, version 30, effective August 10, 2026). Read October 3, 2026.
  4. [clinical-trial] "A randomized clinical trial of cyclosporine in cadaveric renal transplantation." N Engl J Med, 1983;309(14):809-15. PMID: 6350878.
  5. [clinical-trial] Tugwell P, et al. "Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group." N Engl J Med, 1995;333(3):137-41. PMID: 7791814.
  6. [clinical-trial] Sall K, et al. "Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group." Ophthalmology, 2000;107(4):631-9. PMID: 10768324.
  7. [clinical-trial] Frei UA, et al. "Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients. International Sandimmun Neoral Study Group." Transplantation, 1998;65(11):1455-60. PMID: 9645802.
  8. [pubmed] Borel JF. "History of the discovery of cyclosporin and of its early pharmacological development." Wien Klin Wochenschr, 2002;114(12):433-7. PMID: 12422576.
  9. [clinical-trial] Ichai C, et al. "Cyclosporine versus placebo pretreatment of brain-dead donors and kidney graft function (Cis-A-Rein trial): a multicenter, double-blind, randomized, controlled trial." Intensive Care Med, 2026;52(2):289-300. PMID: 41504889.
  10. [pubmed] Pitre T, et al. "Tacrolimus versus cyclosporine immunosuppression in lung transplantation: a systematic review and meta-analysis." BMJ Open Respir Res, 2025;12(1). PMID: 40216413.
  11. [pubmed] Mehreen A, et al. "Efficacy and safety of cyclosporine in colitis: An updated meta-analysis of randomized control trials (1998 to 2024)." Inflammopharmacology, 2025;33(11):6931-6941. PMID: 41065960.
  12. [pubmed] Zhang Y, et al. "Evaluating rituximab against cyclophosphamide or cyclosporine in idiopathic membranous nephropathy: a meta-analysis." Eur J Med Res, 2025;30(1):1228. PMID: 41351015.
  13. [clinical-trial] Zhang Z, et al. "Efficacy and safety of cyclosporine plus luspatercept versus cyclosporine in newly diagnosed non-transfusion-dependent non-severe aplastic anemia: A prospective randomized trial." BMC Med, 2026;24(1). PMID: 42057135.
  14. [pubmed] Chen KY, et al. "Efficacy of Topical Cyclosporine Versus Topical Diquafosol in Treating Dry Eye Disease: A Systematic Review and Meta-Analysis." J Ocul Pharmacol Ther, 2026;42(6):347-355. PMID: 41804812.
  15. [fda-pi] Restasis Multidose (cyclosporine ophthalmic emulsion 0.05%) US prescribing information (DailyMed set 7224d810, version 15, effective August 21, 2025), section 2; read through openFDA October 6, 2026.
  16. [pubmed] Cung TT, et al. "Cyclosporine before PCI in Patients with Acute Myocardial Infarction." N Engl J Med, 2015;373(11):1021-31. PMID: 26321103.
  17. [pubmed] Fervenza FC, et al. "Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy." N Engl J Med, 2019;381(1):36-46. PMID: 31269364.
  18. [pubmed] Kulthanan K, et al. "Cyclosporine for Chronic Spontaneous Urticaria: A Meta-Analysis and Systematic Review." J Allergy Clin Immunol Pract, 2018;6(2):586-599. PMID: 28916431.
  19. [pubmed] Robert N, et al. "Effect of cyclosporine on blood pressure." Cochrane Database Syst Rev, 2010;2010(1):CD007893. PMID: 20091657.
  20. [pubmed] Nighoghossian N, et al. "Cyclosporine in acute ischemic stroke." Neurology, 2015;84(22):2216-23. PMID: 25948727.
  21. [pubmed] González-López JJ, et al. "Topical cyclosporine for atopic keratoconjunctivitis." Cochrane Database Syst Rev, 2012;2012(9):CD009078. PMID: 22972132.
  22. [pubmed] Sridharan K, et al. "Interaction of Citrus Juices with Cyclosporine: Systematic Review and Meta-Analysis." Eur J Drug Metab Pharmacokinet, 2016;41(6):665-673. PMID: 27278683.

Sources & Citations

Studies were read from their PubMed abstracts; the Neoral and Restasis labels from DailyMed through openFDA, read October 6, 2026, alongside the Sandimmune label read October 3.

Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.

Last reviewed: 2026-10-18